Brand New, Unread Copy in Perfect Condition. A+ Customer Service! Summary: Angiogenesis in Cancer; Targeting Angiogenesis for Cancer Therapy; Translating Angiogenesis Inhibitors to the Clinic; Treatment of Specific Cancers with Angiogenesis Inhibitors. Buchnummer des Verkäufers
Inhaltsangabe: Top Investigators Explore the Complexities of Angiogenesis Cancer Research
The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bevacizumab, the first FDA approved angiogenesis inhibitor, with cytotoxic regimens has led to survival benefits in cancer patients. This has raised important questions about the complexities inherent in the clinical application of angiogenesis inhibitors.
Compiles the results of four decades of progress
Integrating fundamental concepts with therapeutic strategies, Anti-Angiogenic Cancer Therapy promotes the idea that an understanding of the molecular and cellular regulation of angiogenesis leads to optimal therapeutic strategies and positive clinical results. It brings together contributions from leading researchers to provide the most authoritative and encyclopedic volume available on this subject.
This volume celebrates progress made in four decades, and more importantly, it provides a clear indication of the complex biology that needs further investigation to realize the possibilities envisioned for this beneficial therapeutic modality.
Über den Autor: Apocell, Inc., Houston, Texas, USA MD Anderson Cancer Center, Houston, Texas, USA University of Texas, M.D. Anderson Cancer Center, Texas, USA
Buchbeschreibung CRC Press. Buchzustand: Very Good. A bright, square, and overall a nice copy All orders guaranteed and ship within 24 hours. Before placing your order for please contact us for confirmation on the book's binding. Check out our other listings to add to your order for discounted shipping. Buchnummer des Verkäufers BOS-H-20d-00010
Buchbeschreibung CRC Press, 2007. Hardcover. Buchzustand: Good. Item may show signs of shelf wear. Pages may include limited notes and highlighting. Includes supplemental or companion materials if applicable. Access codes may or may not work. Connecting readers since 1972. Customer service is our top priority. Buchnummer des Verkäufers mon0000932032
Buchbeschreibung CRC Press, 2007. Hardcover. Buchzustand: New. Buchnummer des Verkäufers SONG0849327997
Buchbeschreibung Buchzustand: Very Good. Book Condition: Very Good. Buchnummer des Verkäufers 97808493279953.0
Buchbeschreibung CRC Press, 2007. Hardcover. Buchzustand: Very Good. Corners bumped. Slight dirty pages outside Next day dispatch. International delivery available. 1000's of satisfied customers! Please contact us with any enquiries. Buchnummer des Verkäufers mon0000181870
Buchbeschreibung CRC Press, 2007. Hardcover. Buchzustand: New. book. Buchnummer des Verkäufers 0849327997
Buchbeschreibung CRC Press, 2007. Buchzustand: very good. Gently used. Expect delivery in 2-3 weeks. Buchnummer des Verkäufers 9780849327995-3
Buchbeschreibung CRC Press, Taylor & Francis Group., 2008. Hardcover. Buchzustand: Fine. 1st Edition. B0K: Fine/, $125.OO 978O849327995 ANTIANGI0GENIC CANCER THERAPY Davis, Darren W.; Herbst, Roy S.; Abbruzzese, James L. CRC Press, Taylor & Francis Group. 2OO8 1st Edition, 1st Printing Green And Black Colored Spine With Title In White Letters, Tall, Wide And Thick Hard Cover BooK: Fine/, 841 Numbered Pages That Were Lightly Read And Are Clean And Tight To The Spine, Slight Shelf, Edge And Corner Wear. Approximately 4 Pages Have Notes. Corners Are Lightly Bumped. Bottom Edge Of The Front Cover Has A Small Nick. D/J: None. Prior Owners Name In The Front Of The BooK, ¿Bing¿. = SYNOPSIS: ¿The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies in cancer research. This work promotes the idea that an understanding of the molecular and cellular regulation of angiogenesis will lead to optimal therapeutic strategies and positive clinical results. It compiles the work of leading experts to explore angiogenesis inhibitors under clinical investigation, as well as early agents used in preclinical studies. It discusses the unique aspects of targeting and inhibiting angiogenesis and the challenges associated with clinical development of angiogenesis inhibitors including trial design and surrogate marker endpoints The chapters are organized to allow readers easy access to the fundamental concepts of angiogenesis and information on the complexities associated with targeting angiogenesis for specific types of cancer¿. This BooK Was Acquired From The Estate Of, Dr. Richard J. Bing, A Research Cardiologist, Composer And Author Who Has Been Called A "Renaissance Man" And ¿A Man For All Seasons¿. D/J: None. This BooK Is Hard To Find, Will Be = Packaged And Shipped Carefully, To Avoid Shipping Damage And Will Make It, An Excellent Addition To Your Own Personal Library Collection, Or As A Gift. Buchnummer des Verkäufers 007386
Buchbeschreibung Buchzustand: New. Zustand des Schutzumschlags: New. Shipped promptly and delivered within 3 to 5 working days. For PO BOX, APO, FPO and Puerto Rico addresses delivery done in 8 to 10 working days. Serving customers since 2006. Thousand of satisfied customers!. Buchnummer des Verkäufers REG_9780849327995_T&F_132
Buchbeschreibung Buchzustand: Brand New. Ships from multiple locations. FedEx or DHL 4-6 business days delivery to your doorstep. Buchnummer des Verkäufers 20JULY16APP-26647